- 4. (once amended) The method of claim 21, wherein said active agent is selected from the group consisting of human CGRP and rat CGRP.
- 6. (once amended) The method of claim 21, wherein said active agent has a purity of at least 95 to 98%.
- 7. (once amended) The method of claim 21, wherein said active agent is dispersed within a composition comprising a pharmaceutically acceptable excipient, liquid or solid carrier.
- 21. (once amended) A method for the reduction of:
  - (i) agonist-induced bronchoconstriction;
  - (ii) agonist-induced bronchospasm;
  - (iii) allergen-induced bronchospasm;
  - (iv) lung inflammation caused by increased eosinophilia;
  - (v) airway hyperreactivity; or
  - (vi) any combination of (i) to (v);

wherein said method comprises the administration of an active agent selected from the group consisting of:

- a) human calcitonin gene-related peptide (human CGRP);
- b) rat CGRP;
- c) diacetoamidomethyl cysteine forms of (a) and (b) ([Cys(ACM)<sup>2,7</sup>]CGRP); and
- d) adrenomedullin.

Please add new claims 27 and 28 as follows:

- 27. (new) The method of claim 4 wherein said active agent is selected from the group consisting of human  $\alpha$  CGRP and rat  $\alpha$  CGRP.
- 28. (new) A method for the reduction of:

3

Atty. Dat. No.: 032931-0218

- (i) agonist-induced bronchoconstriction;
- (ii) agonist-induced bronchospasm;
- (iii) allergen-induced bronchospasm;
- (iv) lung inflammation caused by increased eosinophilia;
- (v) airway hyperreactivity; or
- (vi) any combination of (i) to (v);

wherein said method comprises the administration of an active agent selected from the group consisting of:

- a) human calcitonin gene-related peptide (human CGRP);
- b) rat CGRP;
- c) cow CGRP;
- d) pig CGRP;
- e) chicken CGRP;
- f) frog CGRP;
- g) diacetoamidomethyl cysteine forms of (a) to (f) ([Cys(ACM)<sup>2,7</sup>]CGRP); and
- h) adrenomedullin.

## **REMARKS**

Claims 2, 4 to 8, 21, 27 and 28 are pending. Applicant has cancelled claims 3, 9 to 20 and 22 to 26 without prejudice or disclaimer, amended claims 4, 6, 7 and 21, and added new claims 27 and 28. An Appendix including a marked-up copy of the amendments is attached, showing the changes. The attachment is captioned "Version with markings to show changes made." Former claims 2-26 are rejected under 35 USC §§ 112, 102 and 103. For the reasons outlined below, these rejections are respectfully traversed and reconsideration and withdrawal are respectfully requested.